Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
75 hedge funds and large institutions have $355M invested in Marinus Pharmaceuticals, Inc in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 24 reducing their positions, and 14 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
2% less capital invested
Capital invested by funds: $362M → $355M (-$6.5M)
4% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 24
9% less funds holding
Funds holding: 82 → 75 (-7)
23% less call options, than puts
Call options by funds: $3.34M | Put options by funds: $4.36M
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$5.1M |
| 2 |
VA
VR Adviser
New York
|
+$2.75M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$1.5M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$27.3M |
| 2 |
KPWS
Kestra Private Wealth Services
Austin,
Texas
|
-$2.28M |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$1.16M |
| 4 |
Goldman Sachs
New York
|
-$1.01M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$735K |
MRNS Hedge Fund Activity: Q4 2021 in Review
75 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q4 2021, worth a combined $355M — down 1.8% from $362M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of MRNS and 8 opened new positions — a net loss of 6 holders — while 24 trimmed existing stakes and 23 added.
The largest buyer was Suvretta Capital Management, adding an estimated $5.1M. The largest seller was Boxer Capital, exiting entirely with an estimated $27.3M sold.
- 75 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q4 2021, down from 82 in Q3 2021.
- Funds reported $355M of Marinus Pharmaceuticals, Inc stock for Q4 2021, down 1.8% quarter-over-quarter.
- 8 funds opened new Marinus Pharmaceuticals, Inc positions in Q4 2021 and 14 closed out, a net change of -6 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q4 2021 was Suvretta Capital Management, an estimated $5.1M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q4 2021 was Boxer Capital, an estimated $27.3M sold.
Based on aggregated 13F filings for Q4 2021.